enGene Holdings Inc. (NASDAQ:ENGNW) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGNW) saw a significant increase in short interest in the month of January. As of January 15th, there was short interest totaling 1,537 shares, an increase of 21.7% from the December 31st total of 1,263 shares. Based on an average daily volume of 15,963 shares, the short-interest ratio is presently 0.1 days. Based on an average daily volume of 15,963 shares, the short-interest ratio is presently 0.1 days.

enGene Stock Performance

ENGNW opened at $2.64 on Thursday. The business has a fifty day simple moving average of $2.91 and a 200 day simple moving average of $1.85. enGene has a 1 year low of $0.51 and a 1 year high of $4.20.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.